[Pathophysiological mechanisms of coagulation dysfunction associated with liver disease]

Area of Science:

• Hepatology
• Hematology
• Vascular Biology

Background:

• Liver disease frequently causes coagulation abnormalities, leading to significant bleeding risks.
• Patients with liver disease also exhibit a hypercoagulable state, increasing susceptibility to thrombosis, particularly portal vein thrombosis.
• The hemostatic balance in liver disease patients is fragile, with intertwined risks of bleeding and thrombosis.

Purpose of the Study:

• To elucidate the mechanisms underlying coagulation abnormalities in liver disease.
• To explore the dual risks of bleeding and thrombosis in patients with liver disease.
• To provide insights for dynamic hemostasis management and rebalancing in this population.

Main Methods:

• Review of mechanisms contributing to bleeding in liver disease (e.g., reduced coagulation factor synthesis, thrombocytopenia).
• Analysis of factors promoting thrombosis in liver disease (e.g., altered anticoagulant synthesis, vascular changes, inflammation).
• Discussion of the interplay between bleeding and thrombosis and challenges in management.

Main Results:

• Coagulation abnormalities in liver disease stem from reduced synthesis of procoagulant and anticoagulant factors.
• Hemodynamic changes, vascular intima alterations, inflammation, and pharmacological treatments contribute to both bleeding and thrombosis.
• Patients experience a prolonged state of fragile hemostasis, complicated by genetic factors and procedures.

Conclusions:

• Liver disease presents a complex hemostatic challenge with simultaneous risks of bleeding and thrombosis.
• Understanding the multifaceted mechanisms is crucial for effective management and rebalancing of hemostasis.
• Dynamic monitoring and intervention strategies are essential for improving outcomes in patients with liver disease-related coagulation disorders.